INTRODUCTION
A key step for A3s in blocking viral replication is their encapsidation. For example, murine leukemia virus (MLV) was restricted by human A3B and A3G but not by A3F or murine A3 (mA3) because MLV did not encapsidate either human A3F or mA3 (15, 26) .
For human A3B, A3F, and A3G, their incorporation into HIV-1 is due to their interactions with Gag proteins in the nucleocapsid (NC) region, although it is still unclear whether these interactions are mediated by cellular or viral genomic RNAs (1, 8, 14, 16, 25, 27, 32, 47, 56, 69) . Following entry into the target cell, the virus starts uncoating and ensuing reverse transcription resulting in synthesis of viral minus-strand cDNA. During this process, A3s deaminate dC to form dU on newly synthesized minus-strand viral cDNAs, causing G-to-A mutations on the plus strand DNA and abortive infection (20, 29, 35, 71) . Nonetheless, the viral protein Vif counters the antiviral activity of A3F and A3G by blocking their encapsidation. Vif specifically binds to A3F and A3G (but not A3B) (14, 38, 61) and also interacts with a protein complex containing ElonginB, ElonginC, and Cullin5 (Cul5), which are the core subunits of a Cul5-based E3 ubiquitin ligase such as SCF (66) . SCF belongs to the RING (really interesting new gene) family E3s, which normally contain RING finger proteins such as Ring-box-1 (Rbx1) as another enzymatic component to recruit E2 ubiquitin ligases. Indeed, Vif has a BC-Box motif ( 144 S 145 L 146 Q) that binds to ElonginC (39, 67) and a HCCH motif ( 114 C/ 133 C) that binds to Cul5 (33). Thus, Vif is able to bridge the Cul5-based E3 ligase complex to A3F and A3G and trigger their degradation in the 26S proteasome (31, 38, 50, 53, 72). As a consequence, A3 proteins are excluded from virions and unable to block viral replication.
Interestingly, the activity of Vif is highly species-specific. For example: Vif from HIV-1 blocked A3G from humans and chimpanzees but not monkeys; Vif from SIV isolated from African green monkey (SIVagm) only blocked A3G from the same species; Vif from SIV isolated from rhesus macaque (SIVmac) blocked A3G from human and non-human primates (37) . Indeed, a genetic study revealed that a single residue in the human A3G,
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on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from D128, determined its sensitivity to HIV-1 Vif. This was discovered by the fact that Vif from HIV-1 did not bind to agmA3G because agmA3G contains a lysine (K) rather than aspartate (D) at position 128. When this residue was exchanged between human and agmA3G, human A3G became resistant and agmA3G became sensitive to HIV-1 Vif (3, 36, 48, 62) .
In this report, we studied antiretroviral activities of the human A3DE and A3H
proteins. As previously reported (44), we did not detect any antiretroviral activity of A3H.
However, unlike the previous report (52), we found that A3DE blocked the replication of both HIV-1 and SIV but not MLV although its effect is lower than A3F and AG. The antiretroviral activity of A3DE was accomplished by the encapsidation of A3DE and the resulting mutations of newly synthesized viral minus strand DNA. A3DE and A3G were much more extensively and broadly expressed than A3F in those non-permissive cells and tissues, where they might form an intermolecular complex to combat HIV-1 infection.
Although Vif counteracted its activity, it is clear that A3DE is a new contributor to the intracellular defense network that sets another hurdle to retroviral invasion.
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MATERIALS AND METHODS
Plasmids. HIV-1 proviral constructs, pNL Vif, pNL-Luc, pNL-Luc Vif, and mammalian expression vectors for human AID, A1, A2, A3C, A3F, and A3G and mA3 were described before (72). Human A3A and A3B expression vectors were obtained from Malim (2) , which were subcloned into pcDNA3.1D/V5-His-TOPO (Invitrogen, Carlsbad, CA).
cDNA clones for human A3DE and A3H were commercially obtained (Open Biosystem, Huntsville, AL), and these genes were subcloned into the same vector. All these APOBEC proteins contained a V5 tag at their C-termini. To create plasmids expressing A3 and GST or luciferase fusion proteins, GST and firefly luciferase genes were amplified from pGEX- For example, MLV were produced by to-transfection of 2 μg pCgp, 2 μg pLNCX2-Luc, 5 μg VSV-G, and 16 μg A3. The production of HIV-1 and SIVmac was quantitated by p24 Gag or p27 Gag -capture enzyme-linked immnosorbent assay (ELISA), respectively. The production of SIVagm and MLV was quantitated by viral reverse transcriptase (RT) activity and the reaction cocktail contained 50 mM TrisHCl pH8.0, 75 mM KCl, 2 mM DDT, 24 μg/ml poly rA oligo dT, 5 mM MgCl 2 (SIV) or MnCl 2 (MLV), 1% NP40, and 100 μCi/ml 3 H-dTTP (18) . In some experiments, viruses were further purified by loading onto a 20% sucrose cushion and spun at 27,000 rpm for 2 hr in a Beckman SW28 rotor and viral particles were resuspended in the STE buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 mM EDTA). Equal amounts of viruses were used to infect GHOST-R3/X4/R5 cells. Thirty-six hours later, cells were lysed in a buffer (25 mM Tris-HCl pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% Triton X-100). After removing the nuclei, the cytosolic fraction was used to determine the luciferase activity using a luciferase assay kit (Promega).
Sequencing of newly synthesized viral cDNA and real-time PCR quantitation.
GHOST-R3/X4/R5 cells were infected with various HIV viruses produced from 293T cells, which were passed through 0.22 μm Filter Unit (Millipore, Bedford, MA) and treated with RQ1 RNase-free DNase (Promega) to remove any plasmid DNA contamination. Several hours later, cellular DNAs were extracted by the DNeasy Tissue Kit (QIAGEN Inc., Valencia, CA). A 420 bp fragment was PCR-amplified by a previous primer pair (72) and cloned into pCR4-TOPO vector (Invitrogen). Multiple clones were selected and sequenced by the flanking T3 and T7 primers. Alternatively, the newly synthesized viral cDNA was quantitated by a previously described real-time PCR method with a primer pair MH531 and MH532 and a probe LRT-P (7). As presented in Fig.1 , both of the N and C-terminal Zn 2+ -binding motifs (HxE/PCxxC) and the aspartate (D128) that determines A3G specificity to Vif are all well conserved in these proteins. As A3F and A3G differ by a single amino acid from residues 1 to 61, A3DE and A3B are identical from residues 1 to 57. In addition, A3DE and A3F share 100% homology in exon 5, and they differ in only 3 amino acids in exon 6 where the 2 nd Zn 2+ -binding domain is located. Thus, the N-terminal half of A3DE has very high sequence identity with that of A3B; and the C-terminal half of A3DE has very high sequence identity with that of A3F. In contrast, A3H is much less homologous to A3A and A3C. It shares only 29.6% and 34.7% amino acid sequence with A3A and A3C, respectively, although they all have a highly conserved HxE/PCxxC motif (data not presented).
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Human A3DE blocks HIV-1 replication but Vif counters its activity. The genomic similarity of A3DE and A3H to previously characterized A3 proteins provides a compelling case for determining their roles in ablating HIV-1 replication. A3DE and A3H
were subcloned into the pcDNA3.1 vector, and their anti-HIV activity was compared with human A3A, A3B, A3C, A3F, and A3G proteins. To simplify the measurement of HIV infectivity, the wild type HIV-1 luciferase-reporter virus (pNL-Luc) and its Vif-deletion version (pNL-Luc Vif) were used as before (72). These plasmids were co-transfected into 293T cells with various combinations to produce viruses. As presented in Fig Previously, lower molecular weight products associated with A3G were detected from cell lysates (37). We not only confirmed this observation but also detected similar lower molecular weight products from A3B and A3F-transfected cells. However, it was unclear how these A3 proteins were cleaved. Equal amounts of viruses were then collected to infect GHOST cells and levels of intracellular luciferase activities were measured. As presented in Fig. 2A A3F, and A3G (lanes 9, 10). In contrast, A3H did not block either wild type or Vif-deficient HIV-1 (lanes 15 and 16). To further confirm the effect of A3DE, we titrated its antiretroviral activity. As presented in Fig. 2B , when the amounts of A3DE expression vector were increased from 0 to 0.5, 1, 2 and 4 μg during co-transfection with HIV-1 proviral constructs, the intracellular expression of A3DE increased proportionally. Importantly, only infectivity of the Vif-defective but not wild type HIV-1 was substantially decreased by the dosedependent increase of A3DE expression, which further confirmed that A3DE only blocked the Vif-defective HIV-1 replication. As a comparison, we also titrated A3F and A3G anti-HIV-1 activity in a similar setting. At the highest concentration, A3DE, A3F, and A3G
reduced Vif-deficient HIV-1 infectivity by 7, 25, 100-fold, respectively ( Fig. 2B ), which further confirmed that the anti-HIV-1 activity of A3DE was lower than that of A3F and A3G.
Next, we wanted to test whether A3DE blocks HIV-1 replication when it is expressed endogenously. We generated 293 cell lines stably expressing A3DE, A3F, and A3G ( As noted earlier, a single residue (D128) governs the sensitivity of human A3G to
Vif (3, 36, 48, 62) . This residue is conserved in A3F (E127) and A3DE (D140). To determine whether it governs A3DE sensitivity to Vif, we mutated it to lysine (A3DE D140K ) and similar A3F and A3G mutants were also generated as controls (A3F E127K , and A3G D128K ). Similar to the murine A3 (mA3) that is not sensitive to Vif, A3G D128K blocked the replication of both wild type and Vif-defective HIV-1 ( Fig. 2D , lanes 5 to 8); however, A3DE D140K and A3F E127K were still unable to block the wild type virus (lanes 1 to 4). This result indicates that, unlike in A3G, this conserved residue itself is not sufficient to determine to sensitivity of both A3DE and A3F to Vif. A3G (0.5%) was higher than that by A3DE (0.13%), which might explain why A3G exhibited a higher anti-HIV-1 activity than A3DE. We also detected a relatively high frequency of other types of mutations in these two samples such as A-to-G, A-to-C, C-to-T, and T-to-C.
A3DE induces G-to-
Because these mutations were present in all the samples with a similar frequency, they were most likely errors introduced by viral reverse transcription and/or PCR. Thus, like A3G, A3DE introduced G-to-A hypermutations into HIV-1 genome. Since the G-to-A mutation in viral plus strand DNA correspond to the C-to-U mutation in the minus strand
DNA, these results demonstrate that A3DE exhibits cytidine deamination enzymatic activity in the viral life cycle when Vif is not present.
We further analyzed 57 G-to-A mutations to reveal the consensus sequence for A3DE editing (Fig. 3B ). As previously reported, A3G normally mutates C-residues on the minus strand DNA flanked at the -1 and -2 positions by C residues, resulting in GG-to-AG and GG-to-AA mutations and A3F normally mutates C-residues flanked at the -1 and +1
positions by T residues resulting in GA-to-AA mutations on the plus strand DNA (30, 61).
For A3DE, the mutated C residues were flanked at the -1 by either T or A and the +1 by either G and T residues on the minus strand DNA, resulting in either GA-to-AA or GC-to-AC mutations on the plus strand DNA. Since the GC-to-AC mutation has not been attributed to any other APOBEC family members, it might therefore be used as a genetic marker to trace A3DE activity in vivo.
Because uracil-containing viral cDNA might be degraded by cellular DNA repair enzymes (such as uracil DNA glycosylase and apurinic endonuclease), we next determined the effect of cytidine deamination on the fate of the newly synthesized viral cDNA by realtime PCR. The copy number of HIV-1 reverse transcripts was significantly decreased by both A3DE and A3G when Vif was absent (Fig. 3C) . Thus, we conclude that cytidine deamination is a mechanism of A3DE-mediated antiretroviral activity. (Fig. 2) . To explore this mechanism we first determined whether the presence of Vif resulted in exclusion of A3DE from virion incorporation. Wild type and Vif-defective HIV-1 were produced in the presence of A3DE
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and purified, and A3G was used as a control (Fig. 4A) . Analysis of equal amounts of viral particles (as judged by p24 Gag levels) showed that Vif-defective virions contained significantly greater levels of both A3DE and A3G proteins (Fig. 4A) , which suggests that Vif excludes A3DE from virions. To define further how Vif excluded A3DE from virions, we compared the intracellular levels of A3DE in the presence and absence of Vif. Indeed, in cells expressing Vif, the levels of A3DE were significantly lower (Fig. 4A , middle panel, lane 1). Similarly, the levels of A3G were also decreased in cells expressing Vif (lane 3). Thus, we conclude that Vif destabilizes both A3DE and A3G.
We next developed an in vivo Glutathione S-transferase (GST)-pulldown assay to determine whether Vif could bind to A3DE in cells. We fused a GST tag to the C-terminus of A3A, A3DE, and A3G, and these chimeras were then co-expressed with Vif in 293T cells. Proteins were pulled down by glutathione (GSH)-sepharose beads and all proteins were expressed with predicted size in cells (Fig. 4B , see input lanes, I). However, only A3DE-GST and A3G-GST chimeras were able to pull down Vif (lanes 5 and 7). Thus we conclude that, like A3G, A3DE binds to Vif in vivo.
Finally, we determined whether Vif could trigger the degradation of A3DE in the 26S
proteasome. The interaction between Vif and A3DE implies that A3DE may become another substrate for the Cul5-based E3 ligases. To detect such degradation, we devised a reporter system where the Firefly Luciferase gene (Luc) was fused to the C-terminus of A3 proteins (Fig. 4C ). Our hypothesis was that if Vif triggers the degradation of A3DE, it will also trigger the degradation of A3DE-Luc fusion protein, and therefore, decrease However, due to the high sequence similarity between A3DE and A3F, we found that previously described primers that were used to detect A3F transcripts in different cells and tissues by RT-PCR also amplified A3DE transcripts (data not presented) (2, 14, 61) . Thus,
on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from A3DE could be expressed in those tissues where A3F was detected. To clarify this ambiguity and precisely understand how A3DE and A3F are expressed in vivo, we designed two primer pairs to specifically amplify A3DE and A3F (Fig. 5A ). For comparison, we used a previously described A3G-specific primer pair to amplify A3G transcripts (2). All these primer pairs specifically amplified A3DE, A3F, or A3G, respectively (Fig. 5A) .
Next, these primers were used to determine A3 expression in human cell lines. As To gain further insight into A3DE expression in vivo, we then determined A3 protein expression in human primary tissues (Fig. 5C ). In 29 different human tissue-derived prenormalized cDNA samples, A3G was the most broadly expressed and only absent in pancreas (lane 12). A3F was the least broadly expressed appearing only in tonsil, ovary, normal human tissues, a total of 60, 18, and 76 copies were identified for A3DE, A3F, or A3G, respectively, which confirms the lower expression of A3F in vivo. Intriguingly, the majority of A3DE and A3G were found in those white blood cells that are the same cell population as PBL where A3F was less represented. This result was also consistent with our result in Fig. 5B , where A3F was less expressed than A3DE and A3G in PBL (lane 13).
Thus, A3DE and A3G were much more broadly and abundantly expressed than A3F in human tissues especially in those primary targets for HIV-1 infection. Such a tissuespecific expression pattern may suggest different engagement of these genes in antiretroviral defense.
Although they were expressed differently, A3DE, A3F, and A3G were clearly coexpressed in certain cell lines and tissues ( Fig. 5B and 5C ). A3F and A3G have been previously reported to form heteromultimers (61) and such interaction may coordinate and magnify their antiretroviral effect. To know whether A3DE interacts with A3F and A3G, A3DE-GST (or its control GST) was co-expressed with A3F or A3G, and protein complexes were pulled down by GSH-sepharose beads. As presented in Fig. 5D , both A3F and A3G
were pulled down by A3DE-GST (lanes 2 and 6) but not with GST (lanes 1 and 5). We
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A3DE blocks SIV but not MLV replication. After showing that A3DE inhibited
HIV-1 replication, we next asked whether A3DE could block other retroviruses such as SIV and MLV. To simplify the detection of viral replication, similar luciferase-reporter provirus from SIV and MLV were used. In addition, several other human A3 genes were included in this study to serve as controls. Consistent with prior reports, we found that A3B inhibited the replication of both wild type and Vif-defective SIVagm, SIVmac, and MLV; A3C inhibited the replication of Vif-defective SIVagm and SIVmac; A3F and A3G inhibited the replication of the Vif-defective SIVagm and SIVmac and the wild type SIVagm; A3G inhibited MLV replication (Fig. 6A, 6B , and 6C). We found that A3H did not block any replication of these viruses and A3DE did not block MLV replication. However, A3DE reduced the infectivity of both wild type and Vif-defective SIVagm by 6~8-fold and it also reduced the infectivity of the Vif-defective SIVmac by 6-fold (Fig.6A , B, C). Although its activity of A3DE was relatively weaker than A3F or A3G, it exhibited comparable (in the case of SIVagm) or higher (in the case of SIVmac) antiretroviral activity than A3C. Thus, A3DE blocked the replication of both SIVagm and SIVmac; while, its activity was blocked by Vif from SIVmac but not SIVagm. Fig. 2, 3 , and 6, both A3DE and A3F inhibited the replication of HIV-1 and SIV but not MLV and they both introduced GA-to-AA mutations on the HIV-1 plus strand DNA. Indeed, the C-terminal halves of A3DE and A3F are almost identical ( Fig. 1 ) and such genomic similarity might be the determinant for their quite similar antiretroviral profile.
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Another important observation in this report is that A3DE was more extensively expressed in non-permissive cells and tissues than A3F. Previously, it was found that although A3B, A3F, and A3G blocked HIV replication, they were expressed differently. A3F
and A3G were co-expressed in non-permissive T cells and many tissues including PBL (2, 30, 61) whereas A3B was not detected at all (14) . Nonetheless, using the same RT-PCR strategy, we found that those previously detected A3F mRNAs might also include those from A3DE. In distinguishing of these two mRNA species, we found that A3DE was more broadly and abundantly expressed in non-permissive cells and tissues than A3F. This was seen especially in PBL. Furthermore, it was reported that the HIV-1 genome experienced high number of G-to-A hypermutations in vivo including GG-to-AG, GA-to-AA, GC-AC, and GT-to-AT mutations, where the GG-to-AG and GA-to-AA mutations were attributed to A3G
and A3F, respectively (51). As shown in Fig. 3B , A3DE introduces both GA-to-AA and GCto-AC mutations to HIV-1 genome. Thus, the existence of these GA-to-AA and GC-to-AC mutations from HIV-1 clinical isolates provides important evidence for A3DE activity in vivo.
It therefore seems to be possible that A3DE might play more important role than A3F in complementing the intracellular immunity to HIV-1 by A3G, which has been solely attributed to A3F before.
It is still puzzling why primates encode so many duplicative A3 genes, some of which share the same targets. The existence of such paralogous genes seems functionally redundant, but comparative studies of the antiviral activity of these A3 orthologous genes in humans and monkeys have provided some key implications for understanding this genomic complexity. First, it was shown before that, although A3F exhibited much lower activity to HIV-1 than A3G in humans, this phenotype was reversed in monkeys where A3F exhibited even higher activity than A3G, which suggests that simian A3F preferentially targets HIV-1 instead of SIV (68) . Second, although human A3H did not block any viral replication, macaque A3H efficiently blocked the replication of both SIV and HIV-1 (44) . On the other Unfortunately, lentiviruses, except the equine infectious anemia virus (EIAV), ultimately succeed in infection by expression of Vif, a protein that is able to knock out most of these A3 proteins. Vif has two interfaces to interact with ElonginC and Cul5, which form the core units for the Cul5-based E3 ubiquitin ligase complex. In addition, it also interacts with A3DE, A3F, and A3G. The mechanism by which Vif binds to these different A3
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proteins remains enigmatic. It seems unlikely that these proteins share a similar surface that can be recognized by Vif because a similar negatively charged residue D128 in A3G
that affected its sensitivity to Vif did not play a similar role in A3DE and A3F. More likely, these interactions might not be a direct event and may be mediated by cellular RNA because both Vif and A3 proteins have the capability to bind to RNA (13, 21, 22, 24, 65, 70) . Alternatively, Vif may have additional different interfaces to bind to these different A3 proteins, as suggested by a recent study (58). Nonetheless, understanding these mechanisms will be very helpful for the design of inhibitors that disrupt Vif and A3
interactions, which is of great medicinal importance in HIV/AIDS therapeutics (10, 54). indicated. Intron-exon boundaries information for A3B, A3F, and A3G is from a previous report (22) and that for A3DE is from Ensembl database. GST tag was fused to the C-terminus of A3A (A3A-GST), A3DE (A3DE-GST), and A3G
(A3G-GST), which were followed by another V5 tag. These GST or its fusion proteins were RNAs from these cells were subjected to RT-PCR with A3DE, A3F, and A3G-specific primers and amplified PCR products were visualized by agarose gel electrophoresis followed by EtBr staining. GAPDH was used as an internal control to compare each RNA input. C) Distribution of A3 transcripts in a variety of human tissues. The same primer pairs were used to amplify A3DE, A3F, and A3G messengers from a commercially obtained pre-normalized human multiple tissue cDNA panel by RT-PCR and PCR products were analyzed similarly. D) A3DE interacts with A3F and A3G to form heteromultimers in cells.
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This is a similar experiment as described in Figure 4B . GST or A3DE-GST expression vector was co-transfected with A3F or A3G expression vector into 293T cells. After 48
hours, proteins were pulled down by GSH-Sepharose beads and analyzed by Western blot with a V5 antibody. 
